46 results about "YAP1" patented technology

The present disclosure describes small molecule inhibitors that reduce YAP1 protein levels and therefore inhibit all YAP1 driven processes, including TEAD-mediated transcription. The present disclosure further provides methods of treating cancer utilizing such small molecule inhibitors.

The invention discloses a preparation method of an aloe-emodin regulated Hippo-YAP1 pathway medicine, and relates to the technical field of data encryption, and the preparation method comprises the following steps: S1, providing an aloe-emodin raw material with the purity not lower than 98.32%, the CAS number of the aloe-emodin raw material being 481-72-1, the molecular formula being C15H10O5, and the molecular weight being 270.24; s2, dissolving the aloe-emodin raw material provided in the step S1 into a proper solvent to prepare an aloe-emodin stock solution; the suitable solvent comprises DMSO, and the preparation concentration is not lower than 20.83 mg / mL (77.08 mM); s3, sub-packaging the aloe-emodin stock solution prepared in the step S2, and storing the aloe-emodin stock solution at-80 DEG C for a storage period of not more than 2 years; or storing at-20 DEG C, wherein the storage life is not more than 1 year. The cisplatin and the preparation method thereof show dual beneficial effects of bone protection and tumor sensitization in drug combination, that is, on the premise that the killing effect of cisplatin on osteosarcoma cells is not affected, the normal osteogenesis function is selectively protected, and the anti-tumor synergistic effect is enhanced.

The invention provides an application of an HOXA3 gene as a target spot in screening and treating drugs for hepatocellular carcinoma. Through single-cell multi-omics analysis, the HOXA3 is found to be remarkably and highly expressed in liver cancer tissues and is closely related to poor prognosis of patients. Mechanism research shows that HOXA3 promotes tumor proliferation and metastasis through transcriptional up-regulation of YAP1 and RHOA, and an FGF19-FGFR4 / beta-catenin signal channel positively regulates the expression of HOXA3. The invention verifies that the combined application of the YAP1 inhibitor Verteporfin and the RHOA inhibitor Rhosin can significantly inhibit the HOXA3-mediated liver cancer progress, in-vivo experiments show that the tumor volume is reduced by 68%, the lung metastasis inhibition rate reaches 83%, and an effective treatment strategy is provided for HOXA3 positive hepatocellular carcinoma.